Affiliation:
1. Chinese Academy of Sciences Shenzhen Institutes of Advanced Technology - Shenzhen, Guangdong, CN
2. Xiamen University
3. The First Affiliated Hospital of Shantou University Medical College
4. Chinese Academy of Sciences
Abstract
Abstract
Background: Cuproptosis is a newly defined form of regulated cell death triggered by excess copper and is distinct from other known types of cell death. Currently, reliable prognostic signatures based on cuproptosis-related regulators are underdeveloped. Herein, we aimed to investigate the cuproptosis landscape in lung adenocarcinoma (LUAD).
Materials and Methods:We downloaded gene expression data and corresponding clinical information from The Cancer Genome Atlas and Gene Expression Omnibus. Cuproptosis subtypes were identified using unsupervised clustering based on the expression of 10 cuproptosis-related regulatory genes, including seven positively (FDX1, LIAS, LIPT1, DLAT, DLD, PDHA1, and PDHB) and three negatively (CDKN2A, GLS, and MTF1) correlated genes. CDKN2A expression was detected using immunohistochemistry tissue microarrays.
Results: Unsupervised clustering revealed two LUAD cuproptosis-related subtypes (A and B). Patients with subtype B had a higher survival rate and were significantly enriched in innate immune cells compared to those with subtype A. We built a cuproptosis-related risk model (CRM) to calculate a risk score for each patient; the score was positively correlated with patient prognosis. Somatic mutation landscape analysis revealed a significant negative relationship between tumor mutational burden (TMB) and the CRM score. Patients with both a low CRM score and TMB had the worst prognosis. Immune landscape analysis revealed that patients with a high CRM score had a higher tumor immune dysfunction and exclusion score, suggesting a poorer immunotherapy response rate.
Conclusion: Single-cell CRM score quantification revealed its correlation with the enrichment of different immune cell types in LUAD.
Publisher
Research Square Platform LLC
Reference95 articles.
1. B. C. Bade, and C. S. Dela Cruz, "Lung Cancer 2020: Epidemiology, Etiology, and Prevention," CLINICS IN CHEST MEDICINE, vol. 41, no. 1, pp. 1–24, 2020.
2. "Prospective Comprehensive Molecular Characterization of Lung Adenocarcinomas for Efficient Patient Matching to Approved and Emerging Therapies,";Jordan EJ;Cancer Discovery,2017
3. Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma;Zhang Y;CANCER SCIENCE,2020
4. Targeting of SGK1 by miR-576-3p Inhibits Lung Adenocarcinoma Migration and Invasion,";Greenawalt EJ;MOLECULAR CANCER RESEARCH,2019
5. Personalized therapy for lung cancer: striking a moving target,";Pakkala S;JCI Insight,2018